A cytomegalovirus-based vaccine expressing a single tumor-specific CD8 + T-cell epitope delays tumor growth in a murine model of prostate cancer

Journal of Immunotherapy

Volumn 35, Issue 5, 2012, Pages 390-399

  Klyushnenkova, Elena N ^a,b   Kouiavskaia, Diana V ^a   Parkins, Christopher J ^c   Caposio, Patrizia ^c   Botto, Sara ^c   Alexander, Richard B ^a,b   Jarvis, Michael A ^c,d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

Cancer vaccine; Cytomegalovirus; HLA DR2 transgenic mice; Prostate cancer; Prostate specific antigen

Indexed keywords

CYTOMEGALOVIRUS VACCINE; T LYMPHOCYTE ANTIGEN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; IMMUNE RESPONSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR IMMUNITY;

ADENOCARCINOMA; ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CYTOMEGALOVIRUS; DISEASE MODELS, ANIMAL; EPITOPES, T-LYMPHOCYTE; GENE EXPRESSION; HLA-DRB1 CHAINS; HUMANS; MALE; MICE; MICE, TRANSGENIC; OPEN READING FRAMES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SPLEEN; TUMOR BURDEN; VACCINATION;

EID: 84861233625     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0b013e3182585d50     Document Type: Article

References (51)

1. Han M, Partin AW, Zahurak M, et al. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol. 2003;169:517-523. (Pubitemid 36132976)
2. Drake CG. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol. 2010;10:580-593.
3. Small EJ, Schellhammer PF, Higano CS, et al. Placebocontrolled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089-3094. (Pubitemid 46638945)
4. Klyushnenkova EN, Alexander RB. Challenges to prostate cancer immunotherapy. In: Arnouk H, ed. Advancements in Tumor Immunotherapy and Cancer Vaccines. www.intech open.com/download/pdf/pdfs-id/27446: InTech-Open Access Publisher; 2011:37-62.
5. Thara E, Dorff TB, Pinski JK, et al. Vaccine therapy with sipuleucel-T (Provenge) for prostate cancer. Maturitas. 2011; 69:296-303.
6. Pass RF. Cytomegalovirus. In: David MK, ed. Fields Virology. Philadelphia: Lippincott Williams & Wilkins; 2001:2675-2705.
7. Gillespie GM, Wills MR, Appay V, et al. Functional heterogeneity and high frequencies of cytomegalovirus-specific CD8(+) T lymphocytes in healthy seropositive donors. J Virol. 2000;74:8140-8150. (Pubitemid 30642582)
8. Kern F, Khatamzas E, Surel I, et al. Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. Eur J Immunol. 1999;29:2908-2915. (Pubitemid 30099015)
9. Khan N, Cobbold M, Keenan R, et al. Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype. J Infect Dis. 2002;185:1025-1034. (Pubitemid 34297759)
10. Komanduri KV, Viswanathan MN, Wieder ED, et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med. 1998;4:953-956. (Pubitemid 28364037)
11. Rasmussen L, Matkin C, Spaete R, et al. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J Infect Dis. 1991;164:835-842.
12. Sester M, Sester U, Gartner B, et al. Sustained high frequencies of specific CD4 T cells restricted to a single persistent virus. J Virol. 2002;76:3748-3755. (Pubitemid 34250539)
13. Sylwester AW, Mitchell BL, Edgar JB, et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med. 2005;202:673-685. (Pubitemid 41248418)
14. Waldrop SL, Davis KA, Maino VC, et al. Normal human CD4+ memory T cells display broad heterogeneity in their activation threshold for cytokine synthesis. J Immunol. 1998; 161:5284-5295. (Pubitemid 28519088)
15. Kast WM. Prostate cancer immunotherapy development in prostate specific antigen transgenic mice. www.dtic.mil/cgi-bin/GetTRDoc?AD=ADA380895: Defense Technical Information Center; 1999:1-16.
16. Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med. 2009;15:293-299.
17. Karrer U, Wagner M, Sierro S, et al. Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses. J Virol. 2004;78:2255-2264. (Pubitemid 38228919)
18. Redwood AJ, Messerle M, Harvey NL, et al. Use of a murine cytomegalovirus K181-derived bacterial artificial chromosome as a vaccine vector for immunocontraception. J Virol. 2005;79: 2998-3008. (Pubitemid 40270579)
19. Tsuda Y, Caposio P, Parkins CJ, et al. A replicating cytomegalovirus- based vaccine encoding a single ebola virus nucleoprotein CTL epitope confers protection against ebola virus. PLoS Negl Trop Dis. 2011;5:e1275.
20. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest. 2002;109:409-417. (Pubitemid 34141815)
21. Perambakam S, Hallmeyer S, Reddy S, et al. Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide. Cancer Immunol Immunother. 2006;55:1033-1042. (Pubitemid 43800718)
22. Kouiavskaia DV, Berard CA, Datena E, et al. Vaccination with agonist peptide PSA: 154-163 (155L) derived from prostate specific antigen induced CD8 T-Cell response to the native peptide PSA: 154-163 but failed to induce the reactivity against tumor targets expressing PSA: a phase 2 study in patients with recurrent prostate cancer. J Immunother. 2009;32:655-666.
23. Pavlenko M, Roos AK, Lundqvist A, et al. A phase I trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer. Br J Cancer. 2004;91:688-694. (Pubitemid 39141625)
24. Shahabi V, Reyes-Reyes M, Wallecha A, et al. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother. 2008;57:1301-1313.
25. Lubaroff DM, Konety BR, Link B, et al. Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res. 2009; 15:7375-7380.
26. Madan RA, Arlen PM, Mohebtash M, et al. Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer. Expert Opin Investig Drugs. 2009;18:1001-1011.
27. Seow Y, Wood MJ. Biological gene delivery vehicles: beyond viral vectors. Mol Ther. 2009;17:767-777.
28. Hansen SG, Powers CJ, Richards R, et al. Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science. 2010;328:102-106.
29. Munks MW, Cho KS, Pinto AK, et al. Four distinct patterns of memory CD8 T cell responses to chronic murine cytomegalovirus infection. J Immunol. 2006;177:450-458. (Pubitemid 43939158)
30. Sierro S, Rothkopf R, Klenerman P. Evolution of diverse antiviral CD8+ T cell populations after murine cytomegalovirus infection. Eur J Immunol. 2005;35:1113-1123. (Pubitemid 40542218)
31. Kern ER. Animal Models of Cytomegalovirus Infection: Murine CMV. London: Academic Press; 1999.
32. Kern ER. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res. 2006;71:164-171.
33. Medin JA, Liang SB, Hou JW, et al. Efficient transfer of PSA and PSMA cDNAs into DCs generates antibody and T cell antitumor responses in vivo. Cancer Gene Ther. 2005;12:540-551. (Pubitemid 40686594)
34. Klyushnenkova EN, Kouiavskaia DV, Berard CA, et al. Cutting edge: permissive MHC class II allele changes the pattern of antitumor immune response resulting in failure of tumor rejection. J Immunol. 2009;182:1242-1246.
35. Klyushnenkova EN, Link J, Oberle WT, et al. Identification of HLA-DRB1*1501-restricted T-cell epitopes from prostatespecific antigen. Clin Cancer Res. 2005;11:2853-2861. (Pubitemid 40525183)
36. Madsen LS, Andersson EC, Jansson L, et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet. 1999;23:343-347. (Pubitemid 29526435)
37. Messerle M, Crnkovic I, Hammerschmidt W, et al. Cloning and mutagenesis of a herpesvirus genome as an infectious bacterial artificial chromosome. Proc Nat Acad Sci USA. 1997;94:14759-14763. (Pubitemid 28041447)
38. Arase H, Mocarski ES, Campbell AE, et al. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science. 2002;296:1323-1326. (Pubitemid 34522789)
39. Voigt V, Forbes CA, Tonkin JN, et al. Murine cytomegalovirus m157 mutation and variation leads to immune evasion of natural killer cells. Proc Natl Acad Sci USA. 2003;100: 13483-13488. (Pubitemid 37444768)
40. Uetsuki T, Naito A, Nagata S, et al. Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha. J Biol Chem. 1989;264:5791-5798. (Pubitemid 19098044)
41. Pavlenko M, Leder C, Roos AK, et al. Identification of an immunodominant H-2D(b)-restricted CTL epitope of human PSA. Prostate. 2005;64:50-59. (Pubitemid 40734738)
42. Wagner M, Jonjic S, Koszinowski UH, et al. Systematic excision of vector sequences from the BAC-cloned herpesvirus genome during virus reconstitution. J Virol. 1999;73: 7056-7060. (Pubitemid 29327894)
43. van Hall T, van de Rhee NE, Schoenberger SP, et al. Cryptic open reading frames in plasmid vector backbone sequences can provide highly immunogenic cytotoxic T-lymphocyte epitopes. Cancer Res. 1998;58:3087-3093. (Pubitemid 28335091)
44. Cheroutre H, Madakamutil L. Mucosal effector memory T cells: the other side of the coin. Cell Mol Life Sci. 2005;62:2853-2866. (Pubitemid 41779951)
45. Mackay CR, Marston WL, Dudler L. Naive and memory T cells show distinct pathways of lymphocyte recirculation. J Exp Med. 1990;171:801-817. (Pubitemid 20088983)
46. Masopust D, Vezys V, Marzo AL, et al. Preferential localization of effector memory cells in nonlymphoid tissue. Science. 2001;291:2413-2417. (Pubitemid 32231804)
47. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
48. Zhang H, Podojil JR, Chang J, et al. TGF-beta-induced myelin peptide-specific regulatory T cells mediate antigen-specific suppression of induction of experimental autoimmune encephalomyelitis. J Immunol. 2010;184:6629-6636.
49. Tonkin DR, He J, Barbour G, et al. Regulatory T cells prevent transfer of type 1 diabetes in NOD mice only when their antigen is present in vivo. J Immunol. 2008;181:4516-4522.
50. Mohr CA, Arapovic J, Muhlbach H, et al. A spread-deficient cytomegalovirus for assessment of first-target cells in vaccination. J Virol. 2010;84:7730-7742.
51. Popa M, Ruzsics Z, Lotzerich M, et al. Dominant negative mutants of the murine cytomegalovirus M53 gene block nuclear egress and inhibit capsid maturation. J Virol. 2010; 84:9035-9046.